anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
A method of expressing peptides which are immunologically reactive with antibodies to LAV is disclosed. The peptides are produced by bacterial host cells transformed with a recombinant plasmid which includes appropriate procaryotic transcriptional and translational signals for expression, followed by a DNA sequence coding for a peptide comprising the amino acid sequence as shown in FIG. 5 starting with isoleucine, number 1, and ending with threonine, number 173. The peptides of the present invention are immunologically reactive with antibodies to LAV, or antibodies to viruses defined to be the same as or equivalent to LAV. The peptides produced by the method disclosed may be used to screen for the presence of antibodies to LAV in a biological fluid, to determine the presence of LAV antigen in a biological fluid, or within a method for producing antibodies to LAV through the immunization of an animal with the peptide. Further, the pNEV-3 encoded peptides may be used as a vaccine against infection by the causative virus for acquired immune deficiency syndrome.
PROBLEM TO BE SOLVED: To obtain a new compound generally to be used in the rheumatics- plastic operation area, and useful as a muscle relaxant, anticonvulsant, anti- inflammatory agent or antipodagric drug. SOLUTION: This compound is shown by formula I (R is a group of formula II, HOCH2 -CHOH-CH2 , H2 NCH2 CUOHCH2 , HOOCCH2 or OH-CH2 -CHCl-CH2 ). e.g. 3-demethyl-3-glycidylthiocolchicine. The compound of formula I is obtained, for example, by reaction of a compound of formula III with a compound of formula IV to form a compound of formula V. The compound of formula I is used in the form of ccapsules, tablets, suppository, cream, injectable solution, ointment, etc., using a vehicle and a support. It has been shown in examination that the compound of formula I is high in the affinity for strychnine-sensitive glycine receptors compared to thiocolchicoside as a pseudoalkaloid having been widely used over a very long-term of years in the therapies of gout, a compound structurally analogous to the compound of formula I.
FIELD: cattle breeding. SUBSTANCE: one of prostaglandin $$$ preparation is administrated to pigs at period from 12 to 14-th day of sexual cycle, twice, at interval 8-10 h at the doses introduced for swine. Then gonadotropin from the foaled mare serum is administrated as a single dose after 24-36 h (1200-1500 IU/head) and after 72-80 h - human chorionic gonadotropin (750-1000 IU/head). In 40-42 h after human gonadotropin administration a single pig insemination is carried out and in 16-18 h embryos were isolated. Embryo yield is increased by 2-3-fold as compared with the known methods of superovulation induction. EFFECT: enhanced effectiveness of method. 2 tbl, 2 cl
PAQR4 is an orphan receptor in the PAQR family with an unknown function in metabolism. Here, we identify a critical role of PAQR4 in maintaining adipose tissue function and whole-body metabolic health. We demonstrate that expression of Paqr4 specifically in adipocytes, in an inducible and reversible fashion, leads to partial lipodystrophy, hyperglycaemia and hyperinsulinaemia, which is ameliorated by wild-type adipose tissue transplants or leptin treatment. By contrast, deletion of Paqr4 in adipocytes improves healthy adipose remodelling and glucose homoeostasis in diet-induced obesity. Mechanistically, PAQR4 regulates ceramide levels by mediating the stability of ceramide synthases (CERS2 and CERS5) and, thus, their activities. Overactivation of the PQAR4-CERS axis causes ceramide accumulation and impairs adipose tissue function through suppressing adipogenesis and triggering adipocyte de-differentiation. Blocking de novo ceramide biosynthesis rescues PAQR4-induced metabolic defects. Collectively, our findings suggest a critical function of PAQR4 in regulating cellular ceramide homoeostasis and targeting PAQR4 offers an approach for the treatment of metabolic disorders.
CD38 is expressed on malignant plasma cells. CD28 is a costimulatory molecule required for T-cell activation and survival. Provided herein are novel anti-CD38 antibodies, anti-CD28 antibodies, and bispecific antibodies (bsAbs) that bind to both CD38 and CD28 and act as costimulatory agents to activate T cells via binding CD80 and/or CD86. In certain embodiments, the bispecific antigen-binding molecules of the present invention are capable of inhibiting the growth of tumors expressing CD38. The bispecific antigen-binding molecules of the invention are useful for the treatment of diseases and disorders in which an upregulated or induced CD38-targeted immune response is desired and/or therapeutically beneficial. For example, the bispecific antibodies of the invention are useful for the treatment of various cancers, including multiple myeloma, lymphoma, and leukemia.
The invention discloses an application of a traditional Chinese medicine composition and immune cell combination in preparing a cancer treatment medicine. According to the technical scheme, a synergistic system is formed by orally taking a traditional Chinese medicine formula of specific components in the same period of reinfusion of the CAR-NK cells. The system takes folic acid receptor alpha as a target spot, and relieves the intracellular regulation signal network after the folic acid receptor alpha is combined with folic acid, thereby avoiding the folic acid receptor alpha from being used as a signal molecule to promote the malignant growth of tumors. It has been found in the present invention that after uptake and internalization of folic acid by the body, the folate receptor alpha can be localized to the nucleus as a transcription factor binding cis-regulatory element. Folate receptor alpha directly regulates the expression of key developmental genes in tumor cells through this mechanism. By applying the invention, the expression level of folic acid receptor alpha can be obviously reduced; moreover, compared with the single reinfusion of the CAR-NK cells, the synchronous oral traditional Chinese medicine composition can effectively improve the targeting of the CAR-NK and has stronger killing capacity on the folic acid receptor alpha positive lung cancer cells.
A smoking initiation prevention intervention (called KickAsh! intervention) will be implemented in 12 youth social work organisations offering sport and/or recreational activities, during a period of three months (October 2023 to December 2023).Youth workers will act as implementers of the intervention. Approximately 5 youth workers per organisation will participate in the study. Adolescents participating in the youth social work organisations will receive the intervention. Approximately 25 adolescents per organisation will participate in the study.
This study will evaluate lifting restrictions in the postoperative period after inguinal hernia repair. Patients will be consented to the study via in person and electronic methods. Patients will be asked to answer a questionnaire regarding their current pre-operative activity levels in order to establish a baseline. Patients will undergo surgery according to normal medical recommendations and patient preference. Patients will be randomized into one of two groups: a control group told to practice standard of care at Eastern Colorado VA with return to activity precautions (6 weeks for open surgery, 2 weeks for minimally invasive surgery) and a treatment group told to "return to activity as tolerated/comfortable and stop activity if pain present". Patients will be observed in post-operative clinics and asked clinical questions, as well as questionnaires to assess their surgical experience, when they returned to activity, and overall quality of life. Medical charts will be reviewed in order to compare differences in responses and behaviors between the two groups and these data points will be recorded in a password protected document for data analysis.

This study aims to identify if lengthy recommendations for convalescence after inguinal hernia surgery are necessary and determine the impact of allowing the individual patient to have some autonomy in a recommendation to return to physical activity based on their own comfort level. This study could provide the surgical community with a more structured response after this common surgical procedure, as well as potentially reduce convalescence times for individual patients, leading to less economic burden on the individual and the community with returning to work precautions.
A composition for protecting and treating vaginal viral diseases and uterine cancer comprising the extract of Phellinus mushroom and lactic acid is provided to increase autoimmunity, inhibit proliferation of bacteria and viruses, and maintain the clean state in the vagina of female. The composition for protecting and treating vaginal viral diseases and uterine cancer comprises the extract of Phellinus sps (Berk). Pilat and lactic acid, wherein the composition is liquid or gel; the weight ratio of Phellinus sps (Berk). Pilat extract and lactic acid is 1:10~1; and the Phellinus sps (Berk). Pilat extract is prepared by extracting Phellinus sps (Berk). Pilat with a polar solvent selected from water, C1-C4 lower alcohol and secondary alcohol.
PURPOSE: A process of preparing an onion skin extract capable of maintaining or reducing a body weight by suppressing fat absorption using quercetin as flavonoid contained richly in the skin of onion is provided. Therefore, the extract is effective for treatment of overweight or obesity. CONSTITUTION: The skin of onion is ground and extracted 5 to 50 times with 10 to 95% ethanol. The extract is centrifuged at 5,000 to 20,000rpm, filtered with a filter paper having a hole size of 0.5μm and subjected to ultrafiltration with a 30 to 200 kDa ultrafiltration membrane. Thereafter, the filtrate is concentrated with a reverse osmosis with a salt rejection rate of 45 to 100% or under reduced pressure. The concentrate with an ethanol content of 10 to 30% is spray-dried with hot air at 170 to 250deg.C or concentrated.
OBJECTIVE: Primary ciliary dyskinesia (PCD) severity has been related to genotype and levels of nasal nitric oxide (nNO). The most common TAS2R38 haplotypes (PAV/PAV, PAV/AVI, AVI/AVI) encoding the bitter taste receptor can affect nNO levels and thus could play a role in the susceptibility to respiratory infections. We assessed the impact of these polymorphisms on nNO production and Pseudomonas aeruginosa (P.a.) infections in different PCD genotypes.
METHODS: Prospective, longitudinal, single-centre study in patients with PCD with known genotype and one of three TAS2R38 haplotypes evaluated for up to 10 years. We related nNO values to TAS2R38 haplotypes in all patients, and in the three most frequent genotypes (CCDC39/CCDC40, DNAH5, DNAH11). In the genetic group(s) with different mean trends of nNO in relation to the polymorphism, we evaluated longitudinal lung function as a clinical outcome measure. We also studied any associations between the prevalence of chronic P.a. infection and PAV alleles. Linear mixed-effects models were used to evaluate longitudinal associations.
RESULTS: 119 patients with PCD underwent 1116 study visits. Only in the DNAH11 mutations group was there a mean trend of nNO production which was significantly higher in PAV/PAV than AVI/AVI haplotype (p=0.033), with a better trend in spirometric and plethysmographic parameters. In patients with DNAH11 mutations the PAV allele was also associated with a significantly reduced prevalence of chronic P.a.
CONCLUSION: TAS2R38 may be a modifier gene for PCD severity, but only in mild phenotype disease. Further study of TAS2R38 polymorphisms might enable new management strategies to prevent chronic P.a.
A randomized double-blind placebo-controlled mixed experimental design with three arms (intranasal oxytocin administration vs. oral oxytocin administration vs. placebo administration, each with 60 subjects) will be employed in the current study. 35 minutes after treatment subjects will be applied two different types of pleasant touch (social massage vs. caress-like stroking) to their calf. After each applied touch stimulation session, the subjects will be asked to rate their subjective experience of the touch including the perceived pleasantness, arousal, intensity and payment. The neural basis of touch processing will be measured via simultaneously acquired fNIRS together with skin conductance responses and the electrocardiogram recording. Blood samples will be taken before and after the treatment as well as after each run session to measure plasma oxytocin levels to explore the associations with primary outcome measure (the behavioral and neural measures of touch processing). Mixed-measure analysis of variance (ANOVA) with treatment as between-subject factor and condition as within-subject factor will be used to investigate oxytocin effects on social touch processing.

To control potential confounding effects across groups, before the experiment all participants will be asked to complete a range of Chinese versions of validated questionnaires on personality, traits, attitude towards interpersonal touch and sensitivity to reward: Autism Spectrum Quotient (ASQ), Beck Depression Inventory II (BDI), State-Trait Anxiety Inventory (STAI), the Cheek and Buss Shyness Scale (CBSS), the Adult Attachment Scale (AAS), the Childhood Trauma Questionnaire (CTQ), social touch questionnaire (STQ), Sensitivity to Punishment and Sensitivity to Reward Questionnaire (SPSRQ), Sensory Over-Responsivity (SensOR) Scales and the Interpersonal Reactivity Index (C-IRI). And associations between questionnaire scores (especially the ASQ and STQ scores) with primary outcome measure will be explored to investigate modulatory effects of autistic traits. Additionally, to control for potential confounding effects of treatment on mood across the experiment, the Positive and Negative Affect Schedule (PANAS) will be administered immediately before and 30 minutes after the treatment. Participants will also complete the PANAS after each type of touch condition to further measure the modulatory effects of stroking touch and massage on mood.
Subjects who are diagnosed with HCM and require routine extended cardiac monitoring for risk stratification of sudden cardiac death. All subjects will receive 28 days of external cardiac monitoring.
PURPOSE:An emulsified makeup agent, containing a polyhydric alcohol and/or organic acid salt and an aqueous high polymer, and having high humectant effect on the skin without splashing water even in a container having poor gastightness. CONSTITUTION:An emulsified makeup agent containing 20-50wt% polyhydric alcohol and/or organic acid salt and 0.1-5.0wt% aqueous high polymer, e.g. guar gum, methyl cellulose or carboxyvinyl polymer. The resultant makeup agent has high humectant effect on the skin without splashing water even in a container having poor gastightness, e.g. compact, not in a bottle nor tube, etc. A glycol, glycerol, saccharide and pentaerythritol, etc., may be cited as the polyhydric alocohol, and sodium, potassium and triethanolamine salt, etc. of lactic acid, pyrrolidonecarboxylic acid or tartaric acid, etc. may be cited as the organic acid salt.
This invention generally relates to a novel mRNA composition and its production method useful for developing and manufacturing RNA-based anti-viral and/or anti-cancer vaccines and medicines. The mRNA so obtained is used for making not only preventive but also therapeutic vaccines and/or medicines. This invention includes two types of mRNA constructs, namely “5'-hairpin messenger RNA (5hmRNA)” and “messenger-hairpin-messenger RNA (mhmRNA)”, respectively. In brief, both of 5hmRNA and mhmRNA contain at least a hairpin-like stem-loop RNA structure. The 5hmRNA contains at least a stem-loop RNA structure in the 5'-UTR of a protein/peptide-coding mRNA, while the mhmRNA contains a middle stem-loop structure flanked with two protein/peptide-coding mRNA sequences on both sides. In mhmRNA, the first 5'-mRNA preferably encodes an RNA replicase, such as viral RNA-dependent RNA polymerase (RdRp), for use in amplifying the second 3'-mRNA in transfected cells. After transfection into target cells, both of 5hmRNA and mhmRNA can be further translated into at least a desired protein/peptide for eliciting a pre-designed, desired biological effect or cellular function, including but not limited to inducing specific immune responses, preventing viral infections, suppressing viral replication, inhibiting viral assembly and/or inhibiting tumor/cancer cell growth as well as causing cancer cell death. To produce highly structured 5hmRNA and mhmRNA, a novel PCR-IVT methodology has been developed and used with a specially designed RNA polymerase-helicase mixture activity.
The aim of this study was to evaluate the prognostic value of peripheral blood inflammation indexes in patients with metastatic Colorectal Cancer (CRC) and to establish a predictive scoring system. A total of 324 CRC patients diagnosed through pathological examination from January 2017 to July 2022 at the Third Affiliated Hospital of Kunming Medical University were included. The prognosis of patients with metastatic CRC was examined, and the correlation between IL-10 expression in pathological tissues and IL-10 expression in serum was analyzed. The results showed that the prognosis of CRC was poorer when metastasis occurred (P < 0.001). Additionally, IL-10 was highly expressed in the metastatic CRC group (P = 0.018), and the expression of IL-10 in pathological tissues of patients with metastatic CRC was positively correlated with the expression of IL-10 in serum (P = 0.037). The neutrophil-to-lymphocyte ratio (NLR), lymphocyte-to-white blood cell ratio (LWR), aggregate index of systemic inflammation (AISI), monocyte-to-lymphocyte ratio (MLR), systemic inflammatory response index (SIRI), prognostic nutritional index (PNI), advanced lung cancer inflammation index (ALI), and interleukin-10 (IL-10) were calculated and determined by ROC curve. The critical values were 2.135, 3.735, 353.745, 0.265, 1.025, 52.975, 353.635, and 11.25, respectively. Inflammatory indexes with an AUC of more than 0.6 were selected, and each colorectal cancer patient with any of these risk factors was assigned a score of one. The 324 patients were then divided into two groups: 0-4 for the low-risk group and 4-8 for the high-risk group. The occurrence of distant metastases in the two groups was statistically analyzed. The results showed that the OS and PFS of the low-risk group were significantly superior to those of the high-risk group (P < 0.05). These findings indicate that NLR, LWR, AISI, MLR, SIRI, PNI, ALI, and IL-10 are risk factors for distant metastasis in CRC patients. Therefore, the prediction scores of these indexes can be used to effectively evaluate the prognosis of patients with metastatic CRC.
The invention discloses an antioxidant peptide M8, which contains a linear small peptide with an amino acid sequence shown as SEQ ID NO. 1. The invention also discloses a preparation method of the antioxidant peptide M8, which comprises the following steps: s1, synthesizing to obtain crude polypeptide by using an automatic polypeptide synthesizer according to an amino acid sequence shown in SEQ ID NO. 1; s2, desalting and purifying the crude polypeptide through column chromatography; the mobile phase is acetonitrile and water, the acetonitrile and water contain TFA with the mass concentration of 0.1 percent, and the flow rate is 1-3 ml/min. The invention also discloses application of the antioxidant peptide M8 in preparing antioxidant medicines, food additives and cosmetics. The antioxidant peptide M8 has extremely strong antioxidant activity, and has the characteristics of small molecular weight, simple structure, low hemolytic activity and extremely low cytotoxicity.
Patients will have osteoarthritis (OA) of the knee defined and scored radiologically in Study 1. Patients in Study 2 will also have OA of the knee, but a clinical diagnosis will suffice. All patients will report knee pain.
OBJECTIVE: To explore the clinical characteristics and pathogenic variant in a child with Cantú syndrome (CS).
METHODS: A male who was admitted to the Children's Hospital Affiliated to Zhengzhou University on February 23, 2022 was selected as the study subject. Clinical data of the child was collected. Peripheral blood samples of the child and his parents were collected and subjected to whole-exome sequencing (WES). Candidate variant was verified by Sanger sequencing. This study was approved by the Children's Hospital Affiliated to Zhengzhou University (Ethics No. 2023-K-087).
RESULTS: The child, a 3-year-and-2-month-old male, was born with hirsutism, with heavy hair all over the body and peculiar facial features. Routine echocardiography 1 month before had discovered atrial septal defect. Sequencing revealed that the child has harbored a heterozygous c.2438G>C (p.S813T) variant of the ABCC9 gene, which was de novo in origin. Based on the guidelines from the American College of Medical Genetics and Genomics (ACMG), the c.2438G>C variant was classified as likely pathogenic (PS2+PM2_Supporting+PP3).
CONCLUSION: The heterozygous c.2438G>C variant of the ABCC9 gene probably underlay the pathogenesis of CS in this child.
PROBLEM TO BE SOLVED: To provide a method for finely crystallize cisplatin, capable of obtaining fine cisplatin crystals having excellent particle diameters and an excellent particle size distribution in a good yield without using hydrochloric acid and water by mixing the solution of the cisplatin dissolved in a good solvent with an organic solvent which is a poor solvent for the cisplatin but is miscible with the good solvent. SOLUTION: The good solvent for the cisplatin is preferably a solvent having a solubility of >=10 g/L, especially 20-50 g/L, for the cisplatin at 25 deg.C, and is selected from organic amides and the organic sulfoxides. The organic amides include (N-substituted, N,N-disubstituted) formamides, acetamide, propionamide and cyclic amides such as 2-pyrrolidinone. The organic sulfoxides include lower alkyl group-substituted sulfoxides. The poor solvent is a solvent having a solubility of <=5 g/L, preferably 2 g/L, for the cisplatin at 25 deg.C, and is preferably a lower alkanol such as methanol or a halogeno lower alkane such as chloroform. The fine cisplatin crystals suitable as a medicine are thus obtained by the method.